On Tuesday, Cardiff Oncology Inc (NASDAQ: CRDF) opened higher 11.43% from the last session, before settling in for the closing price of $3.15. Price fluctuations for CRDF have ranged from $2.01 to $5.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.36%. Company’s average yearly earnings per share was noted 15.19% at the time writing. With a float of $60.75 million, this company’s outstanding shares have now reached $66.53 million.
Let’s determine the extent of company efficiency that accounts for 33 employees. In terms of profitability, gross margin is 58.04%, operating margin of -10876.83%, and the pretax margin is -10201.67%.
Cardiff Oncology Inc (CRDF) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cardiff Oncology Inc is 8.68%, while institutional ownership is 42.24%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.49% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Check out the current performance indicators for Cardiff Oncology Inc (CRDF). In the past quarter, the stock posted a quick ratio of 6.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 395.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.94 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Looking closely at Cardiff Oncology Inc (NASDAQ: CRDF), its last 5-days average volume was 1.8 million, which is a jump from its year-to-date volume of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 37.57%.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 43.73%, which indicates a significant increase from 38.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.71% in the past 14 days, which was higher than the 86.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.14, while its 200-day Moving Average is $3.32. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $3.78. Second resistance stands at $4.05. The third major resistance level sits at $4.40. If the price goes on to break the first support level at $3.15, it is likely to go to the next support level at $2.80. Should the price break the second support level, the third support level stands at $2.53.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are currently 66,526K shares outstanding in the company with a market cap of 233.51 million. Presently, the company’s annual sales total 680 K according to its annual income of -45,430 K. Last quarter, the company’s sales amounted to 110 K and its income totaled -13,430 K.
